Zoetis Purchasing PHARMAQ for $765M

Deal designed to strengthen Zoetis' core livestock business, and boost its presence in the fast-growing segment of aquatic health products serving aquaculture

Sanofi Pasteur’s Flu Vaccine Manufacturing Plant Gets FDA Nod

Facility will add 100 million doses to firm’s current 50 million dose capacity. FDA approved Sanofi Pasteur’s new manufacturing facility for the production of seasonal...

Radiant Strikes Deal with Spectrum to Provide CRO Services Across India

Access to both firms' services will be given through a single contract. Radiant Research will forge a partnership with Spectrum Clinical Research to provide CRO...

3D Printed Carrier System Successfully Delivers Immunosuppressive Drug

Scientists in Korea using a 3-D printed drug microcarrier have shown in animal models that the carrier maintained robust integrity and delivered a local, sustained load of cyclosporine A (CsA) in an amount that overcame the need for additional drugs to treat immune rejection.

Allergan Partners with Rugen to Develop ASD, OCD Therapies

Allergan said it will develop new small molecule drugs with Rugen, whose compounds for autism and obsessive compulsive disorder have shown efficacy in animal models

Agenus Buys Celexion’s SECANT Platform, Antibody Assets

$4M-plus acquisition designed to speed up its checkpoint inhibitor collaborations with Merck & Co. and Incyte.

HIV Transmission Blocked by Often Overlooked Class of Antibody

A group of scientists at Texas Biomedical Research Institute have zeroed in on a new defense against HIV-1, the virus that causes AIDS.

Novartis Exercises Global Option for Conatus’ NASH Therapy Emricasan

Novartis will pay Conatus $7M option fee, co-fund existing Phase IIb studies, and fund all Phase III emricasan monotherapy and combination therapy trials

Advinus to Utilize Corning’s Epic Technology for Assay Development and Screening

Indian firm will use label-free detection platform for in-house and contract discovery.

Amgen Anticancer Antibody Bites the Dust

Amgen has pulled the plug on its IGF1R monoclonal antibody candidate ganitumab, after an interim analysis of an ongoing Phase III study failed to show any benefits of combining the drug with gemcitabine therapy in patients with metastatic pancreatic cancer.

Recently Featured

Stay Connected

555,274FansLike
49,779FollowersFollow
Scroll Up